ARIAD’s petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit ARIAD Pharmaceuticals, Inc. and its own co-plaintiffs today announced that the U.S.S. Patent No. ARIAD is the special licensee of the technology and patents. In 2006, the jury in the U.S. The jury awarded damages to the plaintiffs predicated on U.S. Sales of these two drugs through the entire year 2019, when the patent expires. The jury verdict was then upheld in 2007 by Judge Rya W. Zobel of the District Court who also found in favor of the plaintiffs.Our devoted regulatory team liaises with the regulators to make sure efficient management of acceptance processes, which has resulted in executing over 230 BA/End up being studies for ANVISA submissions in Brazil alone until now,’ said Dr. Ashutosh Pudage, President – Bioanalytical on Accutest's accomplishments. Superior quality, adherence to timelines and competitive costs will be the three pillars of an effective CRO. During a preceding expansion phase, Accutest opened offices in the US and in holland. By adding emerging countries, especially in Latin America and in Asia, Accutest shall gain additional benefits which will be offered to its vast clientele..